Literature DB >> 31638088

Role of CD20+ T cells in multiple sclerosis: implications for treatment with ocrelizumab.

Stefan Gingele1, Thomas Skripuletz1, Roland Jacobs2.   

Abstract

Entities:  

Year:  2020        PMID： 31638088     DOI： 10.4103/1673-5374.266913

Source DB:  PubMed          Journal:  Neural Regen Res        ISSN： 1673-5374            Impact factor:   5.135


× No keyword cloud information.
  10 in total

Review 1.  Breaching Brain Barriers: B Cell Migration in Multiple Sclerosis.

Authors:  Carla Rodriguez-Mogeda; Sabela Rodríguez-Lorenzo; Jiji Attia; Jack van Horssen; Maarten E Witte; Helga E de Vries
Journal:  Biomolecules       Date:  2022-06-07

2.  An overview of pivotal trials and real-world evidence for CD20-depleting therapy in multiple sclerosis : Immunotherapy with rituximab, ocrelizumab, and ofatumumab.

Authors:  Arkady Ovchinnikov; Oliver Findling
Journal:  Wien Med Wochenschr       Date:  2022-06-20

3.  Effectiveness of rituximab vs. ocrelizumab for the treatment of primary progressive multiple sclerosis: a real-world observational study.

Authors:  Carmen Alcalá; Carlos Quintanilla-Bordás; Francisco Gascón; Ángel Perez Sempere; Laura Navarro; María Carcelén-Gadea; Lamberto Landete; Javier Mallada; Emmanuel Cañizares; Antonio Belenguer; Sara Carratalá; José Andrés Domínguez; Francisco Carlos Pérez-Miralles; Sara Gil-Perotín; Raquel Gasqué; Laura Cubas; Jéssica Castillo; Bonaventura Casanova
Journal:  J Neurol       Date:  2022-02-02       Impact factor: 4.849

4.  Implications of COVID-19 Outbreak on Immune Therapies in Multiple Sclerosis Patients-Lessons Learned From SARS and MERS.

Authors:  Nora Möhn; Refik Pul; Christoph Kleinschnitz; Harald Prüss; Torsten Witte; Martin Stangel; Thomas Skripuletz
Journal:  Front Immunol       Date:  2020-05-12       Impact factor: 7.561

Review 5.  [Ocrelizumab for treatment of multiple sclerosis].

Authors:  Jonas Graf; Philipp Albrecht; Norbert Goebels; Orhan Aktas; Hans-Peter Hartung
Journal:  Nervenarzt       Date:  2020-06-10       Impact factor: 1.214

Review 6.  Targeting B Cells to Modify MS, NMOSD, and MOGAD: Part 1.

Authors:  Jonas Graf; Jan Mares; Michael Barnett; Orhan Aktas; Philipp Albrecht; Scott S Zamvil; Hans-Peter Hartung
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2020-12-16

Review 7.  Autoreactive lymphocytes in multiple sclerosis: Pathogenesis and treatment target.

Authors:  Rongzeng Liu; Shushu Du; Lili Zhao; Sahil Jain; Kritika Sahay; Albert Rizvanov; Vera Lezhnyova; Timur Khaibullin; Ekaterina Martynova; Svetlana Khaiboullina; Manoj Baranwal
Journal:  Front Immunol       Date:  2022-09-23       Impact factor: 8.786

Review 8.  B cells in multiple sclerosis - from targeted depletion to immune reconstitution therapies.

Authors:  Maria T Cencioni; Miriam Mattoscio; Roberta Magliozzi; Amit Bar-Or; Paolo A Muraro
Journal:  Nat Rev Neurol       Date:  2021-06-01       Impact factor: 42.937

9.  Tumor-Cell-Specific Targeting of Ibrutinib: Introducing Electrostatic Antibody-Inhibitor Conjugates (AiCs).

Authors:  Andreas Faust; Nicole Bäumer; Alina Schlütermann; Manuel Becht; Lilo Greune; Christiane Geyer; Christian Rüter; Renato Margeta; Lisa Wittmann; Petra Dersch; Georg Lenz; Wolfgang E Berdel; Sebastian Bäumer
Journal:  Angew Chem Int Ed Engl       Date:  2021-11-25       Impact factor: 16.823

10.  Rituximab Induces Complete Remission of Proteinuria in a Patient With Minimal Change Disease and No Detectable B Cells.

Authors:  Maximilian Webendörfer; Linda Reinhard; Rolf A K Stahl; Thorsten Wiech; Hans-Willi Mittrücker; Sigrid Harendza; Elion Hoxha
Journal:  Front Immunol       Date:  2021-02-08       Impact factor: 7.561
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.